

Amendments to the Specification

Please replace paragraph [0003] which begins on page 1, line 11, with the following amended paragraph.

[0003] This invention is directed to methods of providing cardioprotection in a patient in need thereof comprising administering to said patient a pharmaceutically effective amount of a compound having adenosine A1/A2 agonistic activity, beginning at a time less than 10 minutes after the onset of reperfusion, at reperfusion, and ten minutes or more before reperfusion, and continuing for a period of more than 30 minutes following the onset of reperfusion.

Please replace paragraph [0036] which begins on page 12, line 9, with the following amended paragraph.

[0036] A first embodiment according to the invention is a method of providing cardioprotection in a patient in need thereof comprising administering to said patient a pharmaceutically effective amount of a compound having adenosine A1/A2 agonistic activity, beginning at a time less than 10 minutes after the onset of reperfusion, and continuing for a period of more than 30 minutes following the onset of reperfusion.

Please replace paragraph [0040] which begins on page 13, line 5 with the following amended paragraph.

[0040] A fifth embodiment according to the invention is a method of protecting against reperfusion injury in a patient in need thereof comprising administering to said patient a pharmaceutically effective amount of a compound having adenosine A1/A2 agonistic activity, beginning at a time less than 10 minutes after the onset of reperfusion, and continuing for a period of more than 30 minutes following the onset of reperfusion.

Please replace paragraph [0044] which begins on page 13, line 25 with the following amended paragraph.

[0044] A ninth embodiment according to the invention is a method of protecting against ischemic injury in a patient in need thereof comprising administering to said patient a pharmaceutically effective amount of a compound having adenosine A1/A2 agonistic activity, beginning at a time less than 10 minutes after the onset of reperfusion, and continuing for a period of more than 30 minutes following the onset of reperfusion.

Please replace paragraph [0048] which begins on page 14, line 15 with the following amended paragraph.

[0048] A thirteenth embodiment according to the invention is a method of providing cardioprotection prior to, during, or following cardiac surgery in a patient in need thereof comprising administering to said patient a pharmaceutically effective amount of a compound having adenosine A1/A2 agonistic activity, beginning at a time less than 10 minutes after the onset of reperfusion, and continuing for a period of more than 30 minutes following the onset of reperfusion.

Please replace the paragraph [0052] which begins on page 15, line 5 with the following amended paragraph.

[0052] A seventeenth embodiment according to the invention is a method of providing cardioprotection prior to, during, or following ischemic attack in a patient in need thereof comprising administering to said patient a pharmaceutically effective amount of a compound having adenosine A1/A2 agonistic activity, beginning at a time less than 10 minutes after the onset of reperfusion, and continuing for a period of more than 30 minutes following the onset of reperfusion.

Please replace the abstract with the following amended abstract (replacement sheet enclosed herewith):

This invention is directed to methods of providing cardioprotection in a patient in need thereof comprising administering to said patient a pharmaceutically effective amount of a compound having adenosine A1/A2 agonistic activity, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, beginning at a time less than 10 minutes after the onset of reperfusion, at reperfusion, and ten minutes or more before reperfusion, and continuing for a period of more than 30 minutes following the onset of reperfusion.